Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

Recursion Pharmaceuticals (NASDAQ:RXRX) Given Buy Rating at Needham & Company LLC

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note